Esperoct
European approval for Novo’s Esperoct in haemophilia A
June 21, 2019Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma
The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
